NDAORALTABLETPriority Review
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
INQOVI (cedazuridine and decitabine) by Taiho Oncology is nucleic acid synthesis inhibitors [moa]. Approved for nucleoside metabolic inhibitor [epc]. First approved in 2020.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INQOVI is an oral combination therapy of cedazuridine and decitabine approved in July 2020 for treating myelodysplastic syndromes by inhibiting nucleic acid synthesis. Decitabine is a nucleoside metabolic inhibitor that works as a DNA methyltransferase inhibitor, while cedazuridine enhances its bioavailability. The combination delivers the first-ever oral formulation of decitabine, replacing intravenous administration.
$0.077BPart D
Peak14.7 years to LOEProduct is at peak commercial maturity with 14.7 years of patent exclusivity remaining, supporting stable team sizing and continued promotional investment.
Mechanism of Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Class:
Nucleoside Metabolic Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Inqovi Maintenance Therapy in Myeloid Neoplasms
Started Sep 2021
22 enrolled
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaStem Cell Leukemia
Career Relevance
INQOVI offers stable, mature-stage career opportunities in a niche oncology franchise with a strong safety profile and 15+ years of market protection. Roles on this product emphasize patient education, provider engagement, and lifecycle management rather than launch excitement, appealing to professionals seeking long-term commercial stability in a specialized indication.
Brand Manager
Worked on INQOVI at Taiho Oncology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.